中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.018 seconds)

    ANTI-CXADR ANTIBODY
    2.
    发明申请
    ANTI-CXADR ANTIBODY 有权
    抗CXADR抗体

    公开(公告)号：US20150140018A1

    公开(公告)日：2015-05-21

    申请号：US14400207

    申请日：2013-05-13

    Applicant: MICROBIAL CHEMISTRY RESEARCH FOUNDATION ,  MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.

    Inventor： Manabu Kawada ,  Hiroyuki Inoue ,  Shuichi Sakamoto ,  Masunori Kajikawa ,  Masahito Sugiura ,  Sakiko Urano

    IPC: C07K16/30 ,  G01N33/574

    CPC classification number: C07K16/30 ,  A61K39/00 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/3069 ,  C07K2317/34 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2333/705

    Abstract: An object is to find a target molecule effective for cancer treatments and the like and to provide an antibody capable of specifically binding to the molecule, an anticancer agent comprising the antibody as an active ingredient, and so forth. Hence, prostate cancer cell lines (LNCaP-CR cells and LNCaP cells) were compared by SST-REX, and CXADR was identified as a molecule involved in tumor formation and so on. Then, a monoclonal antibody against CXADR was prepared, and the anti-cancer activity, ADCC activity, CDC activity, and so forth were examined. The result revealed that an antibody capable of binding to an epitope present at positions 181 to 230 of a CXADR protein derived from human exhibited an anti-cancer activity against prostate cancer cells, pancreatic cancer cells, and colorectal cancer cells. Further, it was also revealed that the antibody had an ADCC activity and a CDC activity. Moreover, the structures of light chain and heavy chain variable regions of the antibody were successfully determined.

    Abstract translation: 目的是找到对癌症治疗等有效的靶分子，并提供能够特异性结合分子的抗体，包含抗体作为活性成分的抗癌剂等。 因此，通过SST-REX比较前列腺癌细胞系（LNCaP-CR细胞和LNCaP细胞），将CXADR鉴定为涉及肿瘤形成的分子等。 然后，制备针对CXADR的单克隆抗体，检测抗癌活性，ADCC活性，CDC活性等。 结果表明，能够结合存在于衍生自人的CXADR蛋白的第181至230位的表位的抗体对前列腺癌细胞，胰腺癌细胞和结肠直肠癌细胞具有抗癌活性。 此外，还显示抗体具有ADCC活性和CDC活性。 此外，成功测定了抗体轻链和重链可变区的结构。

    Anti-CXADR antibody
    5.
    发明授权
    Anti-CXADR antibody 有权
    抗CXADR抗体

    公开(公告)号：US09416189B2

    公开(公告)日：2016-08-16

    申请号：US14400207

    申请日：2013-05-13

    Applicant: MICROBIAL CHEMISTRY RESEARCH FOUNDATION ,  MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.

    Inventor： Manabu Kawada ,  Hiroyuki Inoue ,  Shuichi Sakamoto ,  Masunori Kajikawa ,  Masahito Sugiura ,  Sakiko Urano

    IPC: C07K16/30 ,  G01N33/574 ,  A61K39/395 ,  C07K16/28 ,  A61K39/00

    CPC classification number: C07K16/30 ,  A61K39/00 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/3069 ,  C07K2317/34 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2333/705

    Abstract: An object is to find a target molecule effective for cancer treatments and the like and to provide an antibody capable of specifically binding to the molecule, an anticancer agent comprising the antibody as an active ingredient, and so forth. Hence, prostate cancer cell lines (LNCaP-CR cells and LNCaP cells) were compared by SST-REX, and CXADR was identified as a molecule involved in tumor formation and so on. Then, a monoclonal antibody against CXADR was prepared, and the anti-cancer activity, ADCC activity, CDC activity, and so forth were examined. The result revealed that an antibody capable of binding to an epitope present at positions 181 to 230 of a CXADR protein derived from human exhibited an anti-cancer activity against prostate cancer cells, pancreatic cancer cells, and colorectal cancer cells. Further, it was also revealed that the antibody had an ADCC activity and a CDC activity. Moreover, the structures of light chain and heavy chain variable regions of the antibody were successfully determined.

    Abstract translation: 目的是找到对癌症治疗等有效的靶分子，并提供能够特异性结合分子的抗体，包含抗体作为活性成分的抗癌剂等。 因此，通过SST-REX比较前列腺癌细胞系（LNCaP-CR细胞和LNCaP细胞），将CXADR鉴定为涉及肿瘤形成的分子等。 然后，制备针对CXADR的单克隆抗体，检测抗癌活性，ADCC活性，CDC活性等。 结果表明，能够结合存在于衍生自人的CXADR蛋白的第181至230位的表位的抗体表现出对前列腺癌细胞，胰腺癌细胞和结肠直肠癌细胞的抗癌活性。 此外，还显示抗体具有ADCC活性和CDC活性。 此外，成功测定了抗体轻链和重链可变区的结构。

Patent Agency Ranking